Suppr超能文献

卵黄样营养不良:美国明尼苏达州奥尔姆斯特德县的患病率。

Vitelliform dystrophies: Prevalence in Olmsted County, Minnesota, United States.

作者信息

Dalvin Lauren A, Pulido Jose S, Marmorstein Alan D

机构信息

a Department of Ophthalmology , Mayo Clinic , Rochester , Minnesota , USA.

b Department of Molecular Medicine , Mayo Clinic , Rochester , Minnesota , USA.

出版信息

Ophthalmic Genet. 2017 Mar-Apr;38(2):143-147. doi: 10.1080/13816810.2016.1175645. Epub 2016 Apr 27.

Abstract

BACKGROUND

Vitelliform dystrophies are a group of macular degenerative diseases characterized by round yellow lesions in the macula. While often idiopathic, vitelliform dystrophies include inherited maculopathies such as Best disease and some cases of pattern dystrophy. The prevalence of vitelliform dystrophies in the United States has not been reported. This study examined the prevalence of vitelliform dystrophies in Olmsted County, Minnesota.

MATERIALS AND METHODS

The Rochester Epidemiology Project database was used to identify all cases of vitelliform or pattern dystrophy in Olmsted County from 1 January 2000-31 December 2014.

RESULTS

Overall, 27 patients had true vitelliform lesions, indicating a prevalence of 1 in 5500. Of these, two had genetically confirmed Best disease, and an additional five to seven carried a diagnosis of Best disease, which chart reviews confirmed as probable cases; 18-20 patients had adult-onset vitelliform macular dystrophy. The prevalence of Best disease was 1 in 16,500 to 1 in 21,000. Adult-onset vitelliform macular dystrophy was found in 1 in 7400 to 1 in 8200.

CONCLUSIONS

Vitelliform dystrophies affect 1 in 5500 individuals in Olmsted County. While the values in this study provide good estimates for the prevalence of Best disease versus adult-onset vitelliform macular dystrophy, the results are limited by dependence on diagnoses made by other ophthalmologists and underutilization of genetic testing. Thus, these diseases should be thought of as at least as prevalent as reported here. As therapies for Best disease and other macular degenerative diseases are quickly becoming a reality, genetic testing should be employed as the gold standard for diagnosis of these diseases.

摘要

背景

卵黄样营养不良是一组以黄斑区圆形黄色病变为特征的黄斑变性疾病。虽然通常为特发性,但卵黄样营养不良包括遗传性黄斑病变,如Best病和一些图案状营养不良病例。美国卵黄样营养不良的患病率尚未见报道。本研究调查了明尼苏达州奥尔姆斯特德县卵黄样营养不良的患病率。

材料与方法

利用罗切斯特流行病学项目数据库,确定2000年1月1日至2014年12月31日期间奥尔姆斯特德县所有卵黄样或图案状营养不良病例。

结果

总体而言,27例患者有真正的卵黄样病变,患病率为1/5500。其中,2例经基因确诊为Best病,另外5至7例诊断为Best病,病历审查确认为可能病例;18 - 20例患者患有成人型卵黄样黄斑营养不良。Best病的患病率为1/16500至1/21000。成人型卵黄样黄斑营养不良的患病率为1/7400至1/8200。

结论

卵黄样营养不良影响奥尔姆斯特德县1/5500的个体。虽然本研究中的数据为Best病与成人型卵黄样黄斑营养不良的患病率提供了较好的估计,但结果受限于依赖其他眼科医生做出的诊断以及基因检测利用不足。因此,这些疾病的实际患病率应至少与本研究报道的一样高。由于针对Best病和其他黄斑变性疾病的治疗方法正迅速成为现实,基因检测应作为诊断这些疾病的金标准。

相似文献

1
Vitelliform dystrophies: Prevalence in Olmsted County, Minnesota, United States.
Ophthalmic Genet. 2017 Mar-Apr;38(2):143-147. doi: 10.1080/13816810.2016.1175645. Epub 2016 Apr 27.
2
Near-infrared fundus autofluorescence in subclinical best vitelliform macular dystrophy.
Am J Ophthalmol. 2014 Dec;158(6):1247-1252.e2. doi: 10.1016/j.ajo.2014.08.028. Epub 2014 Aug 28.
3
Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes.
Ophthalmology. 2014 Dec;121(12):2406-14. doi: 10.1016/j.ophtha.2014.06.028. Epub 2014 Jul 29.
4
Electrooculography and optical coherence tomography reveal late-onset Best disease.
Optom Vis Sci. 2014 Nov;91(11):e274-7. doi: 10.1097/OPX.0000000000000403.
5
Frequency, genotype, and clinical spectrum of best vitelliform macular dystrophy: data from a national center in Denmark.
Am J Ophthalmol. 2012 Aug;154(2):403-412.e4. doi: 10.1016/j.ajo.2012.02.036. Epub 2012 May 24.
6
[Choroidal neovascularization complicating Best's vitelliform macular dystrophy in a child].
J Fr Ophtalmol. 2016 Jan;39(1):69-73. doi: 10.1016/j.jfo.2015.05.008. Epub 2015 Dec 18.
7
Multimodal imaging in a case of best vitelliform macular dystrophy.
Eur J Ophthalmol. 2021 Sep;31(5):2189-2190. doi: 10.1177/11206721211008779. Epub 2021 Apr 7.
8
Preferential hyperacuity perimeter in best vitelliform macular dystrophy.
Retina. 2011 May;31(5):959-66. doi: 10.1097/IAE.0b013e3181f441c1.
10
Novel BEST1 Mutations and Special Clinical Features of Best Vitelliform Macular Dystrophy.
Ophthalmic Res. 2016;56(4):178-185. doi: 10.1159/000444681. Epub 2016 Apr 15.

引用本文的文献

2
Advancing Insights into Pediatric Macular Diseases: A Comprehensive Review.
J Clin Med. 2025 Jan 18;14(2):614. doi: 10.3390/jcm14020614.
3
Phenotype and genetic spectrum of six Indian patients with bestrophinopathy.
Taiwan J Ophthalmol. 2024 Dec 3;14(4):602-608. doi: 10.4103/tjo.TJO-D-24-00080. eCollection 2024 Oct-Dec.
4
12-year cumulative incidence rate of rare retinal diseases: a nationwide study in Korea.
Eye (Lond). 2025 Apr;39(6):1170-1174. doi: 10.1038/s41433-024-03565-5. Epub 2025 Jan 4.
5
Adult-onset foveomacular vitelliform dystrophy: epidemiology, pathophysiology, imaging, and prognosis.
Front Ophthalmol (Lausanne). 2023 Aug 10;3:1237788. doi: 10.3389/fopht.2023.1237788. eCollection 2023.
6
Optical Coherence Tomography in Inherited Macular Dystrophies: A Review.
Diagnostics (Basel). 2024 Apr 24;14(9):878. doi: 10.3390/diagnostics14090878.
7
Nationwide epidemiologic survey on incidence of macular dystrophy in Japan.
Jpn J Ophthalmol. 2024 May;68(3):167-173. doi: 10.1007/s10384-024-01060-8. Epub 2024 Apr 3.
9
Gene therapy in bestrophinopathies: Insights from preclinical studies in preparation for clinical trials.
Saudi J Ophthalmol. 2023 Dec 1;37(4):287-295. doi: 10.4103/sjopt.sjopt_175_23. eCollection 2023 Oct-Dec.

本文引用的文献

1
BEST1: the Best Target for Gene and Cell Therapies.
Mol Ther. 2015 Dec;23(12):1805-9. doi: 10.1038/mt.2015.177. Epub 2015 Sep 21.
4
Using Stem Cells to Model Diseases of the Outer Retina.
Comput Struct Biotechnol J. 2015 May 6;13:382-9. doi: 10.1016/j.csbj.2015.05.001. eCollection 2015.
5
Adult-onset foveomacular vitelliform dystrophy: A fresh perspective.
Prog Retin Eye Res. 2015 Jul;47:64-85. doi: 10.1016/j.preteyeres.2015.02.001. Epub 2015 Feb 11.
6
Long-Term Results of Photodynamic Therapy for Choroidal Neovascularization in Pediatric Patients with Best Vitelliform Macular Dystrophy.
Ophthalmic Genet. 2015 Jun;36(2):168-74. doi: 10.3109/13816810.2015.1009121. Epub 2015 Feb 12.
7
Bevacizumab treatment for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy.
Eur J Ophthalmol. 2014 Nov-Dec;24(6):890-6. doi: 10.5301/ejo.5000486. Epub 2014 May 20.
8
iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration.
Hum Mol Genet. 2013 Feb 1;22(3):593-607. doi: 10.1093/hmg/dds469. Epub 2012 Nov 8.
9
Frequency, genotype, and clinical spectrum of best vitelliform macular dystrophy: data from a national center in Denmark.
Am J Ophthalmol. 2012 Aug;154(2):403-412.e4. doi: 10.1016/j.ajo.2012.02.036. Epub 2012 May 24.
10
Functional roles of bestrophins in ocular epithelia.
Prog Retin Eye Res. 2009 May;28(3):206-26. doi: 10.1016/j.preteyeres.2009.04.004. Epub 2009 May 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验